Do Weight Loss Drugs Lower Blood Pressure? A Closer Look at the Science
New weight loss medications show promise in lowering blood pressure, but questions remain about long-term benefits and safety.
Do Weight Loss Drugs Lower Blood Pressure?
The link between obesity and high blood pressure is well established, but new research suggests that some of the latest weight loss medications—specifically tirzepatide and semaglutide—might do more than help people shed pounds: they may also significantly lower blood pressure, offering cardiovascular benefits beyond weight loss itself.
How Weight and Blood Pressure Are Connected
High blood pressure (hypertension) is more common in people who are overweight or obese. Excess weight strains the heart and blood vessels, leading to increased blood pressure. Traditional approaches to managing hypertension in people with obesity focus on lifestyle changes—such as diet, exercise, and stress management—and, when necessary, medications specifically targeted to lower blood pressure. However, for many, weight loss itself can reduce blood pressure, allowing some to lower or even discontinue their blood pressure medications.
For years, doctors have advised that losing 5% to 10% of body weight can lead to meaningful improvements in blood pressure, reducing the risk of heart disease and stroke. The question now is whether newer weight loss medications can accelerate or enhance these benefits, especially for individuals who struggle to lose weight through lifestyle changes alone.
The Rise of New Weight Loss Medications
In recent years, a new generation of weight loss drugs has emerged, including GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic) and dual agonists like tirzepatide (Zepbound, Mounjaro). These medications mimic naturally occurring hormones that regulate appetite and blood sugar, leading to significant weight loss for many people.
Does Tirzepatide Lower Blood Pressure?
Groundbreaking research published in the journal Hypertension examined whether tirzepatide, already approved for obesity and type 2 diabetes, could lower blood pressure in adults with obesity but without diabetes. The study, a sub-analysis of the larger SURMOUNT-1 weight loss trial, followed nearly 500 participants over 36 weeks.
Key Findings
- Participants taking 5 mg of tirzepatide experienced an average systolic blood pressure reduction of 7.4 mm Hg.
- Those on 10 mg saw an average reduction of 10.6 mm Hg.
- The 15 mg group had an average reduction of 8.0 mm Hg.
- Blood pressure-lowering effects were evident during both day and night, with nighttime reductions particularly noteworthy because elevated nighttime blood pressure is a stronger predictor of cardiovascular death.
It’s important to note that these reductions were seen even in participants who were already on blood pressure medications, and in those whose blood pressure was not technically classified as “high” at the study’s outset. The findings suggest that tirzepatide’s benefits may extend beyond weight loss to directly improve cardiovascular risk factors in people with obesity.
What About Semaglutide?
Semaglutide, another GLP-1 receptor agonist, has also been studied for its effects on cardiovascular risk factors. According to recent research, people taking semaglutide for weight loss experienced greater decreases in blood pressure and triglyceride levels compared to placebo groups, along with a reduced risk of cardiovascular events such as heart attack and stroke. However, not all studies agree: some sources report minimal or no effect on blood pressure, highlighting the need for further investigation.
How Do Other Weight Loss Medications Affect Blood Pressure?
Not all weight loss medications have the same effects on blood pressure. Here’s how some other common options compare:
| Medication | Effect on Blood Pressure | Notes |
|---|---|---|
| Phentermine | Generally decreases | Most studies show blood pressure reductions, even in people with hypertension, though monitoring is advised due to stimulant properties. |
| Naltrexone-Bupropion (Contrave) | Slight increase | May cause small increases in systolic blood pressure and pulse, likely due to bupropion’s effects. |
| Orlistat | Limited evidence | Weight loss itself may reduce blood pressure, but direct drug effects are unclear. |
| Liraglutide (Saxenda) | Modest reduction | Similar to other GLP-1 agonists, but less studied than semaglutide or tirzepatide. |
Why Does Blood Pressure Matter in Obesity?
High blood pressure is a leading risk factor for heart disease, stroke, kidney disease, and premature death. The American Heart Association reports that nearly half of U.S. adults have hypertension, and the overlap with obesity is substantial. Because obesity and hypertension often occur together, strategies that address both conditions simultaneously—like the new weight loss medications—could have a major public health impact.
How Do These Drugs Work?
Tirzepatide and semaglutide work by mimicking hormones that regulate appetite and blood sugar. By acting on receptors in the brain and gut, they help people feel full sooner and reduce food intake. Weight loss naturally improves many cardiovascular risk factors, including blood pressure, but these medications may also have direct effects on blood vessel function and heart health.
Are There Risks or Side Effects?
While the blood pressure benefits of tirzepatide and semaglutide are promising, these drugs are not without side effects. Common issues include nausea, vomiting, diarrhea, constipation, and, less commonly, pancreatitis or gallbladder problems. People with a history of certain types of thyroid cancer should not use these medications. Always consult a healthcare provider to assess individual risks and benefits.
What Are the Long-Term Implications?
The current studies show significant benefits over several months, but important questions remain:
- Will these blood pressure reductions last if the medication is stopped?
- Do the benefits continue over years, reducing the risk of heart attacks, strokes, and death?
- Are there populations for whom these medications are less effective or less safe?
Ongoing and future research will be critical to answer these questions and fully understand the role of these medications in managing obesity and hypertension.
Practical Takeaways for Patients and Providers
For people with obesity and high blood pressure, especially those who have struggled with traditional weight loss methods, these new medications offer a promising additional tool. However, they are not magic bullets. Lifestyle changes remain foundational, and medications should be used as part of a comprehensive treatment plan under medical supervision.
Frequently Asked Questions (FAQs)
Q: Do all weight loss drugs lower blood pressure?
A: No, the effect varies by medication. Tirzepatide and semaglutide have shown significant blood pressure-lowering effects in studies, while naltrexone-bupropion may slightly increase blood pressure.
Q: Can I stop my blood pressure medication if I start a weight loss drug?
A: Never stop or change your blood pressure medication without consulting your healthcare provider. While weight loss (and some weight loss medications) can lower blood pressure, your doctor will need to monitor your response and adjust your medications accordingly.
Q: Are these medications safe for everyone with obesity?
A: These drugs are not appropriate for everyone. People with a history of certain types of thyroid cancer, pancreatitis, or other specific conditions should avoid them. Discuss your medical history with your provider before starting any new medication.
Q: How long do the blood pressure benefits last?
A: Current studies show benefits during the treatment period (up to 36 weeks for tirzepatide), but it’s unclear if these effects persist after stopping the medication. Long-term studies are needed.
Q: Are there any serious side effects?
A: Most side effects are gastrointestinal (nausea, vomiting, diarrhea), but rare serious risks include pancreatitis and thyroid tumors. Discuss potential risks with your healthcare provider.
Conclusion
The latest weight loss medications, especially tirzepatide and semaglutide, represent a significant advance for people with obesity and hypertension. Their ability to lower blood pressure—potentially reducing the risk of heart disease and stroke—is an exciting development, but more research is needed to fully understand their long-term impact. As always, lifestyle changes remain the cornerstone of treatment, and any decision to use medication should be made in partnership with a healthcare provider.
References
- https://newsroom.heart.org/news/new-weight-loss-medication-may-help-lower-blood-pressure-in-adults-with-obesity
- https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00883/full
- https://www.massgeneralbrigham.org/en/about/newsroom/articles/weight-loss-drug-reduces-heart-disease-risk-study
- https://magazine.ucsf.edu/weight-loss-drugs-too-good-to-be-true
- https://obesitymedicine.org/blog/5-common-weight-loss-medications-their-side-effects-obesity-medicine-association/
- https://nyulangone.org/news/can-weight-loss-drug-protect-your-heart-dr-howard-weintraub-explains
- https://www.mayoclinic.org/diseases-conditions/high-blood-pressure/expert-answers/blood-pressure-medication/faq-20058056
Similar Articles
Read full bio of Sneha Tete
